116680-01-4

116680-01-4 structure

Name: Mycophenolate mofetil hydrochloride
Chemical Name: 2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate,hydrochloride
CAS Number: 116680-01-4
Molecular Formula: C₂₃H₃₂ClNO₇
Molecular Weight: 469.96
Catalog: Research Areas Cancer
Create Date: 2017-03-26 01:50:37
Modify Date: 2026-07-01 21:13:31
Mycophenolate mofetil (RS 61443) hydrochloride is a immunosuppressant, a non-competitive, selective and reversible inhibitor of inosine monophosphate dehydrogenase (IMPD) type I/II with IC50s of 39 nM and 27 nM, respectively.

Name	2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate,hydrochloride
Synonyms	Rs 61 Mycophenolate Mofetil Hydrochloride API Cellct 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, hydrochloride, (4E) 2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-isobenzofuran-5-yl)-4-methyl-hex-4-enoate hydrochloride Unii-uxh81S8zvb Mycophenolate mofetil HCl Mycophenolate Mofetil Hydrochloride D4Q: What is Mycophenolate Mofetil Hydrochloride D4 Q: What is the CAS Number of Mycophenolate Mofetil Hydrochloride D4 Q: What is the storage condition of Mycophenolate Mofetil Hydrochloride D4 Q: What e the applications of Mycophenolate Mofetil Hydrochloride D4 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, hydrochloride, (E)

Description	Mycophenolate mofetil (RS 61443) hydrochloride is a immunosuppressant, a non-competitive, selective and reversible inhibitor of inosine monophosphate dehydrogenase (IMPD) type I/II with IC50s of 39 nM and 27 nM, respectively.
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others
Target	Human Endogenous Metabolite
References	[1]. Nakanishi, T., et al., Effect of the inosine 5'-monophosphate dehydrogenase inhibitor BMS-566419 on rat cardiac allograft rejection. Int Immunopharmacol, 2010. 10(1): p. 91-7. [2]. Dehghani, F., et al., Inhibition of microglial and astrocytic inflammatory responses by the immunosuppressant mycophenolate mofetil. Neuropathol Appl Neurobiol, 2010. 36(7): p. 598-611. [3]. Ozgen, M., et al., Mycophenolate mofetil and daclizumab targeting T lymphocytes in bleomycin-induced experimental scleroderma. Clin Exp Dermatol, 2012. 37(1): p. 48-54.

Hazard Codes	Xi

622-40-2

111512-13-1

116680-01-4

Literature: SANDOZ AG Patent: WO2005/23791 A2, 2005 ; Location in patent: Page/Page column 14 ;